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P U B L I S H E D B Y E L S E V I E R I N C .LettersIncidence of Metabolic
Risk Factors Among
Healthy Obese Adults
20-Year Follow-UpThere is growing evidence that obese adults without
metabolic risk factor clustering (the so-called “healthy
obese”) progress to unhealthy obesity over time (1).
However, the pathophysiological changes underlying
the long-term transition into an unhealthy obese state
have not been well characterized. To inform clinical
management of healthy obesity, we aimed to identifyFIGURE 1 Incidence of Metabolic Risk Factors Among Initially Healt
Over 20 Years (n ¼ 1,120)
Results are incidence ratios and 95% conﬁdence intervals (CI) for havin
regression models with robust error variances. Models are adjusted for
cholesterol or triglycerides was observed between groups. Baseline hea
pertension, low high-density lipoprotein cholesterol, high triglycerides,the metabolic risk factors responsible for this transi-
tion, as well as the timing of their onset.
Repeat clinical data were drawn from the Whitehall
II cohort study of British adults. We grouped partici-
pants as normal-weight (body mass index [BMI] 18.5
to 24.9 kg/m2), overweight (BMI 25 to 29 kg/m2), or
obese (BMI $30 kg/m2), and as healthy (2) if they were
free of any the following characteristics: high-density
lipoprotein cholesterol <1.03 mmol/l (men) and <1.29
mmol/l (women); blood pressure $130/85 mm Hg or
antihypertension medication use; fasting plasma
glucose $5.6 mmol/l or diabetic medication use;
triglycerides $1.7 mmol/l; and homeostatic model–
assessed insulin resistance >2.83 (baseline 90th
percentile value). Participants provided writtenhy Obese Compared With Initially Healthy Normal-Weight Adults
g each metabolic risk factor at follow-up, on the basis of Poisson
age, sex, and ethnicity. Little difference in high-density lipoprotein
lthy status is deﬁned as having none of 5 metabolic risk factors (hy-
insulin resistance, and high blood glucose).
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872informed consent. The University College London
research ethics committee provided ethical approval.
Cross-tabulations were used to describe incidence
of each of these 5 metabolic risk factors at 5- (1997 to
1999), 10- (2002 to 2004), 15- (2007 to 2009), and 20-
year (2012 to 2014) follow-ups for healthy normal-
weight, overweight, or obese participants at baseline
(1992 to 1994). Poisson regression models with robust
error variances were used to estimate age-, sex-, and
ethnicity-adjusted incidence ratios and 95% conﬁ-
dence intervals for having each metabolic risk factor
at follow-up for healthy obese compared with healthy
normal-weight adults at baseline.
Among 2,878 adults with anthropometric and
metabolic risk factor data at each time point, 1,120
adults (39 to 61 years of age; 68% male) were free of all
metabolic risk factors at baseline. This initially healthy
status was progressively rarer among those in higher
BMI groups, representing 51.5%, 25.8%, and 13.4%
of normal-weight, overweight, and obese adults,
respectively. Of the healthy obese participants, 57.1%
had at least 1 metabolic risk factor at the 5-year follow-
up, with corresponding proportions being 64.3% at 10
years and 78.6% at 20 years. These proportions were
smaller (32.8%, 46.7%, and 60.3%) among initially
healthy normal-weight participants.
After 5 years (Figure 1), relative to initially healthy
normal-weight adults, initially healthy obese adults
were 4.40 times more likely to be insulin resistant,
3.35 times more likely to have high blood glucose,
and 1.92 times more likely to be hypertensive (all
p < 0.05). Incident insulin resistance remained higher
over all subsequent follow-ups among baseline
healthy obese compared with healthy normal-weight
adults. Case numbers were small for 20-year inci-
dence of low high-density lipoprotein cholesterol
(2 cases) and high triglycerides (3 cases) among
healthy obese adults, with little difference in risk
compared with healthy normal-weight adults over
time. Additional data are available on request.
The risk of developing insulin resistance, high
blood glucose, and hypertension was 2 to 5 times
higher among initially healthy obese adults com-
pared with their healthy normal-weight counterparts,
and these changes were evident after only 5 years of
follow-up. There was little difference in progression
to dyslipidemia. However, the key factor explaining
the long-term decline of healthy obesity was insulin
resistance, which was consistently most common
among healthy obese adults over time.
Healthy obese adults are known to experience
an elevated future risk of type 2 diabetes (3) and
cardiovascular disease (4) compared with healthy
normal-weight counterparts. That insulin resistanceis an established indicator of future impaired glucose
metabolism (5) may explain their much higher inci-
dence of type 2 diabetes (relative risk near 4.0) (3) and
slightly higher incidence of cardiovascular disease
(relative risk near 1.2) (4), given that earlier onset of
risk factors leads to a greater cumulated exposure and
higher disease risk. Overall, our ﬁndings suggest that
healthy obesity is strongly linked with future insulin
resistance that subsequently induces cardiometabolic
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Magnetic Resonance
Imaging in Evaluation of
Pediatric Patients for
Arrhythmogenic Right
Ventricular Dysplasia/
CardiomyopathyIn the March 17, 2015 issue of the Journal, Etoom et al.
(1) reported interesting ﬁndings about the role of
cardiovascular magnetic resonance (CMR) for diag-
nosis of arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C) in children. The results of
Etoom et al. (1) are unique in that there are few other
studies on children with ARVD/C. For the revised
Task Force Criteria (TFC), only 9 of 108 (8%) probands
were diagnosed in subjects between 12 and 18 years of
age (mean 38  13 years of age) (2,3). The study sub-
jects of Etoom et al. (1) averaged 13.8  3.2 years of
age, without a given age range. As such, the extrap-
olation of the revised TFC to children studied by
Etoom et al. must be considered experimental.
A particularly vexing problem is trying to “validate”
CMR for ARVD/C while also using CMR to diagnose
ARVD/C. For Etoom et al. (1), therewas no independent
anatomic comparator for CMR, because echocardiog-
raphy had little or no contribution to the diagnosis
(only 2 patients met major echocardiographic criteria).
The children described by Etoom et al. (1) had
large right ventricles (mean right ventricular [RV]
end-diastolic volume 118 mL/m2), suggesting severe
disease. Although CMR is well suited to identify
RV abnormalities in that setting, it is surprising
that echocardiography was unable to capture these
ﬁndings.
There are a number of other challenges that the
authors faced in applying the revised TFC. Their paper
reports that minor diagnostic criteria were equally
represented in all groups and therefore not included in
the statistical model. However, T-wave inversions in
the precordial leads cannot be counted in children#14
years of age, because this is a nonspeciﬁc ﬁnding at this
age (3). The authors should specify an age cutoff in
their analyses. Genetic testing was only performed in
49 of 142 study subjects. Less speciﬁc 1994 TFC were
used for endomyocardial biopsy. Finally, the authorscombined patients who met the TFC ($4 diagnostic
points) with patients who had only 3 diagnostic points.
We do not think that patients with 3 points should be
classiﬁed as deﬁnite ARVD/C, especially in family
members who receive a major criterion (2 points)
merely by their family history (3).
In our own transatlantic series of >1,000 patients
with ARVD/C, only 4 of 416 probands were present in
patients <13 years of age (4). In our experience,
children with ARVD/C typically have electrocardio-
graphic and Holter abnormalities before CMR changes.
Structural abnormalities in children with ARVD/C are
often mild, and involve focal subtricuspid dyskinesia
with preserved global function rather than severe RV
enlargement. As such, we do not routinely advise CMR
in children <10 years of age. In addition, a high per-
centage of false positive interpretation of CMRs from
referring centers in the North American study suggests
that misinterpretation of CMRs is common (2).
Nevertheless, Etoom et al. (1) have raised an
important question of applicability of revised TFC in
children. Their patient population is worthy of more
in-depth study due to the early age at which they
have expressed disease, perhaps representing an
aggressive form of disease that is otherwise not
commonly seen.Anneline S.J.M. te Riele, MD
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